Adagio Therapeutics (ADGI) News Today → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ADGI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAdagio Therapeutics GAAP EPS of -$0.36 beats by $0.15msn.com - November 9 at 5:43 PMOur Favorite Advent Calendarsnytimes.com - October 10 at 7:44 AMAdagio Therapeutics GAAP EPS of -$0.46 misses by $0.11msn.com - August 11 at 4:40 PMDEADLINE TODAY: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firmbenzinga.com - April 3 at 8:52 AMINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses to Contact the Firmmarkets.businessinsider.com - March 30 at 5:56 PMFILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Invivyd, Inc. – IVVD, ADGIbenzinga.com - March 3 at 2:22 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGIbenzinga.com - February 9 at 12:37 AMForm 8.3 - Horizon Therapeutics Plcfinance.yahoo.com - January 25 at 10:57 PMInvivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshopbenzinga.com - December 19 at 9:32 AMAdagio Therapeutics, now Invivyd, retools its strategy after losing two executivesbizjournals.com - October 17 at 3:15 PMAdagio Therapeutics, Inc.: Adagio Therapeutics Announces Corporate Name Change to Invivydfinanznachrichten.de - September 15 at 9:07 AMInvivyd Announces Multiple Next Generation COVID-19 Antibodytmcnet.com - September 12 at 3:44 PMInvivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variantsfinance.yahoo.com - September 12 at 8:22 AMShort Interest in Adagio Therapeutics, Inc. (NASDAQ:ADGI) Drops By 13.2%marketbeat.com - August 31 at 3:18 AMHedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%247wallst.com - August 22 at 11:25 PMAdagio Therapeutics (NASDAQ:ADGI) Shares Gap Up on Insider Buying Activitymarketbeat.com - August 22 at 10:31 AMMarc Elia Buys 584,451 Shares of Adagio Therapeutics, Inc. (NASDAQ:ADGI) Stockmarketbeat.com - August 19 at 5:15 PMQ3 2022 EPS Estimates for Adagio Therapeutics, Inc. (NASDAQ:ADGI) Decreased by Jefferies Financial Groupmarketbeat.com - August 18 at 8:22 AMAdagio Therapeutics GAAP EPS of -$0.47seekingalpha.com - August 17 at 4:50 AMAdagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlightsfinance.yahoo.com - August 15 at 7:11 PMAdagio Therapeutics, Inc. (NASDAQ:ADGI) Short Interest Up 7.9% in Julymarketbeat.com - August 15 at 1:31 AMIs Adagio Therapeutics (NASDAQ:ADGI) In A Good Position To Invest In Growth?finance.yahoo.com - July 6 at 5:04 PMAdagio Elevates Interim Chief Executive David Hering To Permanent CEOnasdaq.com - July 5 at 6:15 PMMithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy Campaignfinance.yahoo.com - July 5 at 6:15 PMAdagio Announces David Hering Named Permanent Chief Executive Officer and Directorfinance.yahoo.com - July 5 at 8:03 AM(ADGI) News: Did You Lose Money on Your Adagio Therapeutics Investment? Stock Price has Plummeted Since IPO - Contact Johnson Fistelbenzinga.com - July 2 at 5:22 PMAdagio Therapeutics (NASDAQ:ADGI) PT Lowered to $3.00 at Morgan Stanleymarketbeat.com - May 17 at 11:11 AMAdagio Therapeutics Reports Q1 Net Loss of $100.7M, Cash Position of $532.2Minvesting.com - May 13 at 5:39 PMAdagio Therapeutics Reports First Quarter 2022 Financial Resultsfinance.yahoo.com - May 13 at 5:39 PMAdagio stock falls after pausing filing plans for COVID therapy with FDAseekingalpha.com - April 14 at 11:36 AMAdagio Therapeutics Provides Update on Timing of Adintrevimab EUA Requestfinance.yahoo.com - April 14 at 11:36 AMWhen Will Adagio Therapeutics, Inc. (NASDAQ:ADGI) Breakeven?finance.yahoo.com - April 7 at 3:50 PMThe Petri Dish: Adagio says its antibody works against omicron nowbizjournals.com - March 31 at 6:17 AMPeering Into Adagio Therapeutics Inc. - Common Stock's Recent Short Interestmsn.com - March 30 at 3:14 PMThiel-backed venture firm Mithril seeks to nominate candidates for Adagio's boardnasdaq.com - March 30 at 3:14 PMMid-Afternoon Market Update: Dow Drops 100 Points; Adagio Therapeutics Shares Spike Highermarkets.businessinsider.com - March 30 at 3:14 PMAdagio's stock jumps as company says it will seek authorization for COVID-19 antibody treatmentfinance.yahoo.com - March 30 at 3:14 PMAdagio Stock Spikes on New Data, but Its Omicron Problems Remainfinance.yahoo.com - March 30 at 3:14 PMWHO urges countries to keep up COVID-19 testing and surveillance as the viral outbreak remains a global pandemicfinance.yahoo.com - March 30 at 3:14 PMWhy Adagio Therapeutics Stock Is Soaring Todayfinance.yahoo.com - March 30 at 3:14 PMWhy Is Adagio Therapeutics (ADGI) Stock Up Today?investorplace.com - March 30 at 1:04 PMAdagio stock soars 78% as COVID drug ADG20 meets main goals in trial; EUA filing in Q2seekingalpha.com - March 30 at 8:27 AMAdagio Therapeutics Says Its Investigational Drug For Covid-19 Met Primary Endpointsnasdaq.com - March 30 at 8:27 AMAdagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorizationfinance.yahoo.com - March 30 at 8:27 AMAdagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer | Morningstarmorningstar.com - February 26 at 12:01 AMAdagio Therapeutics names David Hering as interim CEOseekingalpha.com - February 24 at 7:58 AMAdagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officerfinance.yahoo.com - February 24 at 7:58 AMAdagio falls after announcing resignation of CEOseekingalpha.com - February 22 at 4:16 PMAdagio Therapeutics Announces ADG20 Development Plans and Pipeline Updatesfinance.yahoo.com - February 22 at 4:16 PMAdagio CEO Gerngross to exit Covid antibody company he foundedfinance.yahoo.com - February 22 at 4:16 PM Get Adagio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADGI and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… ADGI Media Mentions By Week ADGI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADGI News Sentiment▼0.000.44▲Average Medical News Sentiment ADGI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADGI Articles This Week▼00▲ADGI Articles Average Week Get Adagio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADGI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alector News Today Exscientia News Today Taysha Gene Therapies News Today Editas Medicine News Today Fate Therapeutics News Today Mesoblast News Today C4 Therapeutics News Today Tourmaline Bio News Today Valneva News Today Novavax News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADGI) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
